T cell dysfunction and therapeutic intervention in cancer
Top Cited Papers
- 18 July 2024
- journal article
- review article
- Published by Springer Nature in Nature Immunology
- Vol. 25 (8) , 1344-1354
Abstract
Recent advances in immunotherapy have affirmed the curative potential of T cell-based approaches for treating relapsed and refractory cancers. However, the therapeutic efficacy is limited in part owing to the ability of cancers to evade immunosurveillance and adapt to immunological pressure. In this Review, we provide a brief overview of cancer-mediated immunosuppressive mechanisms with a specific focus on the repression of the surveillance and effector function of T cells. We discuss CD8+ T cell exhaustion and functional heterogeneity and describe strategies for targeting the molecular checkpoints that restrict T cell differentiation and effector function to bolster immunotherapeutic effects. We also delineate the emerging contributions of the tumor microenvironment to T cell metabolism and conclude by highlighting discovery-based approaches for developing future cellular therapies. Continued exploration of T cell biology and engineering hold great promise for advancing therapeutic interventions for cancer.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA279926-01, CA253188, CA281868)
- American Lebanese Syrian Associated Charities
- Alex Lemonade Stand Young Investigator Grant
- Deutsche Forschungsgemeinschaft (SFB1371, ZE 832/6-1, ZE 832/8-1)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI105887, AI131703, AI150241, AI150514, Al140761)
This publication has 164 references indexed in Scilit:
- Inosine induces stemness features in CAR-T cells and enhances potencyCancer Cell, 2024
- Metabolic programming and immune suppression in the tumor microenvironmentCancer Cell, 2023
- Spatially organized multicellular immune hubs in human colorectal cancerCell, 2021
- In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8+ T cell fate decisionsCell, 2021
- Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor ImmunityCell, 2020
- De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell RejuvenationCell, 2017
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor ActivityCell, 2016
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell ResponsesCell, 2015
- Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.The EMBO Journal, 1992